Jeffrey Matous, MD, discusses outcomes from the phase 1b MonumenTAL-2 trial with the combination of talquetamab and pomalidomide in patients with relapsed/refractory multiple myeloma.
Related Keywords
Colorado ,United States ,Talquetamab Pomalidomide ,Jeffrey Matous ,University Of Colorado ,Colorado Blood Cancer Institute ,Refractory Multiple ,Ash Annual Meeting And Exposition ,Onclive Tv ,Multiple Myeloma ,
comparemela.com © 2020. All Rights Reserved.